Covidien Spin-Out Mallinckrodt Makes First Move With $1.3B Cadence Buy
This article was originally published in The Pink Sheet Daily
In its first big deal since spinning out last July, the Irish-based specialty pharma is gaining a hospital-based sales and marketing team, a high-margin recently launched pain product and NOLs to gain tax advantages.
You may also be interested in...
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?
An estimated 400 million people globally are infected with hepatitis B, which can result in liver cancer and cirrhosis. Recent advances in RNA and other technologies may provide movement toward a cure, but it’s not clear yet if the biopharma industry will find the economics motivating enough for an all-out effort.